TY  - JOUR
A1  - Dreischulte, Tobias
A1  - Sanftenberg, Linda
A1  - Hennigs, Philipp
A1  - Zöllinger, Isabel
A1  - Schwaiger, Rita
A1  - Floto, Caroline
A1  - Sebastiao, Maria
A1  - Kühlein, Thomas
A1  - Hindenburg, Dagmar
A1  - Gagyor, Ildikó
A1  - Wildgruber, Domenika
A1  - Hausen, Anita
A1  - Janke, Christian
A1  - Hölscher, Michael
A1  - Teupser, Daniel
A1  - Gensichen, Jochen
T1  - Detecting medication risks among people in need of care: performance of six instruments
JF  - International Journal of Environmental Research and Public Health
N2  - Introduction: Numerous tools exist to detect potentially inappropriate medication (PIM) and potential prescribing omissions (PPO) in older people, but it remains unclear which tools may be most relevant in which setting. Objectives: This cross sectional study compares six validated tools in terms of PIM and PPO detection. Methods: We examined the PIM/PPO prevalence for all tools combined and the sensitivity of each tool. The pairwise agreement between tools was determined using Cohen’s Kappa. Results: We included 226 patients in need of care (median (IQR age 84 (80–89)). The overall PIM prevalence was 91.6 (95% CI, 87.2–94.9)% and the overall PPO prevalence was 63.7 (57.1–69.9%)%. The detected PIM prevalence ranged from 76.5%, for FORTA-C/D, to 6.6% for anticholinergic drugs (German-ACB). The PPO prevalences for START (63.7%) and FORTA-A (62.8%) were similar. The pairwise agreement between tools was poor to moderate. The sensitivity of PIM detection was highest for FORTA-C/D (55.1%), and increased to 79.2% when distinct items from STOPP were added. Conclusion: Using a single screening tool may not have sufficient sensitivity to detect PIMs and PPOs. Further research is required to optimize the composition of PIM and PPO tools in different settings.
KW  - inappropriate medication
KW  - prescribing omission
KW  - nursing home residents
KW  - polypharmacy
KW  - adverse drug reaction
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304921
SN  - 1660-4601
VL  - 20
IS  - 3
ER  - 
TY  - JOUR
A1  - Kirsten, Natalia
A1  - Ohm, Frenz
A1  - Gehrdau, Kathrin
A1  - Girbig, Gefion
A1  - Stephan, Brigitte
A1  - Ben-Anaya, Nesrine
A1  - Pinter, Andreas
A1  - Bechara, Falk G.
A1  - Presser, Dagmar
A1  - Zouboulis, Christos C.
A1  - Augustin, Matthias
T1  - Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
JF  - Life
N2  - Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.
KW  - hidradenitis suppurativa
KW  - biologics
KW  - TNF alpha
KW  - adverse drug reaction
KW  - biosimilar
KW  - drug effectiveness
KW  - switching
KW  - adalimumab
KW  - registry
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288213
SN  - 2075-1729
VL  - 12
IS  - 10
ER  -